Animal Biotechnology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Diagnostics Tests is the fastest growing sector, North America is the largest market

The Global Animal Biotechnology Market is projected to expand from USD 25.93 Billion in 2025 to USD 45.29 Billion by 2031, registering a compound annual growth rate of 9.74%. This sector applies molecular biology and genetic engineering principles to alter the genomes of terrestrial and aquatic species for the creation of agricultural, industrial, and pharmaceutical products.

A key force propelling this market is the rising global demand for high-quality animal protein, which necessitates biotechnological interventions to improve disease resistance and livestock productivity. Additionally, the industry is driven by an increasing focus on sustainable food security, encouraging the development of animals that require fewer resources and have a reduced environmental impact. Highlighting this need, the Food and Agriculture Organization reported that global meat production grew by 1.7% to 379 million tonnes in 2024, emphasizing the urgency for advanced biotechnological solutions to meet this escalating supply requirement.

A major obstacle potentially hindering the growth of the global animal biotechnology market is the complicated and often fragmented regulatory environment for genetically engineered animals. Differing ethical standards and inconsistent approval processes across various international jurisdictions create significant trade barriers and slow down the commercialization of innovative products. This regulatory uncertainty increases the capital and time needed for development, which can discourage investment and effectively stall the wider adoption of new technologies within the industry.

Market Drivers

The growth of the companion animal healthcare and wellness sector serves as a primary catalyst for market progression, fueled by the increasing humanization of pets. As owners place greater importance on the longevity and quality of life of their animals, there is a distinct shift toward precision medicine, requiring advanced biotechnological interventions such as genetic screening and monoclonal antibody therapies. This demand prompts biotechnology firms to adapt human-grade medical technologies for veterinary use, opening up profitable avenues for industry expansion. For instance, the American Pet Products Association revealed in its March 2024 'State of the Industry' presentation that total U.S. pet industry expenditures hit $147.4 billion in 2023, indicating a robust consumer willingness to invest in animal well-being that directly supports the research and commercialization of specialized biopharmaceuticals.

Furthermore, government initiatives and funding for veterinary biotechnology research and development strengthen the market's trajectory by mitigating risks associated with early-stage innovation and infrastructure development. Public sector grants are crucial for advancing complex technologies like gene editing and synthetic biology, which often face high financial hurdles before becoming commercially viable. Illustrating this support, UK Research and Innovation announced in February 2024 a £100 million investment to fund six new Engineering Biology Mission Hubs aimed at addressing global challenges, including those in food systems. These strategic investments allow private entities to scale operations and bring scientific breakthroughs to the global market more efficiently, a potential evidenced by Zoetis Inc., which reported revenue of $8.5 billion for the full year 2023 in its February 2024 financial results.

Market Challenges

The intricate and often disjointed regulatory landscape governing genetically engineered animals constitutes a formidable barrier to the growth of the global animal biotechnology market. Disparate approval processes and varying ethical guidelines across international jurisdictions create significant trade hurdles, forcing companies to navigate a patchwork of compliance requirements that delays commercialization. This lack of harmonization increases the financial risk for developers, who must invest substantial resources without the guarantee of global market access, thereby deterring venture capital and stifling innovation.

The extended timelines associated with these regulatory burdens further exacerbate the challenge, as companies cannot quickly recoup their investments. According to the Animal Health Institute, in 2024, the development of a new livestock pharmaceutical required an average of 8.5 years and an investment of approximately $30.5 million. Such prolonged duration and high capital expenditure prevent smaller biotech firms from entering the sector and slow the overall adoption of advanced animal health solutions essential for meeting global productivity demands.

Market Trends

The widespread adoption of CRISPR-Cas9 and precision genome editing is transitioning from experimental phases to commercial reality, fundamentally altering livestock disease management strategies. This trend is exemplified by the regulatory progression of gene-edited animals designed to resist devastating viral pathogens, thereby reducing economic losses and minimizing the industry's reliance on pharmaceuticals. A pivotal market milestone occurred when regulatory bodies began clearing these engineered traits for the food supply chain, validating the technology's safety and utility. According to Genus plc, April 2025, in the 'PRRS Resistant Pig - FDA Approval' announcement, the U.S. Food and Drug Administration approved the company's PRRS-resistant pig, a development crucial for addressing a disease that increases the need for antibiotics by more than 200% in affected herds.

Concurrently, the sector is witnessing a decisive shift toward DNA and mRNA-based veterinary vaccine platforms, driven by the urgent need for rapid response capabilities against transboundary animal diseases. Companies are aggressively capitalizing specialized manufacturing infrastructure to support these complex biologics, moving away from slower, traditional vaccine production methods. This focus on advanced large-molecule production capacity is critical for scaling novel therapeutic and preventative solutions to meet global demand. According to Merck Animal Health, May 2025, in the 'Merck Animal Health and State of Kansas Announce $895 Million Investment' press release, the company allocated $895 million to expand its facility in De Soto, Kansas, specifically to enhance filling and freeze-drying capacity for large molecule vaccines and biologic products.

Key Market Players

• Zoetis Inc
• Boehringer Ingelheim GmbH
• Biogenesis Bago SA
• Merck & Co., Inc.
• Virbac SA
• Elanco LLC
• IDEXX Laboratories Inc
• Heska Corp
• Indian Immunologicals Ltd
• Hester Biosciences Limited

Report Scope

In this report, the Global Animal Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Biotechnology Market, by Product Type:

• Diagnostics Tests
• Vaccines
• Drugs
• Reproductive and Genetic
• Feed Additives

Animal Biotechnology Market, by Application:

• Diagnosis of Animal Diseases
• Treatment of Animal Diseases
• Preventive Care of Animals
• Drug Development
• Others

Animal Biotechnology Market, by Animal Type:

• Companion
• Livestock

Animal Biotechnology Market, by End-use:

• Laboratories
• Point-of-care testing/In-house Testing
• Veterinary Hospitals & Clinics
• Others

Animal Biotechnology Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Biotechnology Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.